Health
100 Most Popular
Pharmaceutical

Pfizer

$41.92
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.03 (0.07%) Today
-$0.04 (-0.08%) After Hours

Why Robinhood?

You can buy or sell Pfizer and other stocks, options, ETFs, and crypto commission-free!

About

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. Read More The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Employees
92,400
Headquarters
New York, New York
Founded
1849
Market Cap
233.12B
Price-Earnings Ratio
21.52
Dividend Yield
3.16
Average Volume
23.07M
High Today
$42.31
Low Today
$41.87
Open Price
$42.06
Volume
5.04M
52 Week High
$46.47
52 Week Low
$35.32

Collections

Health
100 Most Popular
Pharmaceutical
Manufacturing
Healthcare
Medical

News

MarketWatch20h

Pfizer's Lyrica doesn't meet endpoint in epilepsy study

Pfizer Inc. PFE, +0.07% said late Friday one of its drugs did not meet set goals for the treatment of epilepsy in a late stage clinical trial. Pfizer said a Phase 3 clinical trial showed its drug Lyrica did not significantly reduce seizures in epilepsy patients compared with those given a placebo. Lyrica is already approved by the Food and Drug Administration to treat fibromyalgia, diabetic nerve pain, spinal cord injury nerve pain and pain after shingles. Pfizer shares, which closed up less than 0.1% at $4...

126
Seeking AlphaMay 22

Pfizer Posts Positive Phase 3 Study In Eczema, Catalysts Remain In Second Half Of 2019

Pfizer (PFE) announced that it had achieved positive top-line results for its phase 3 study using abrocitinib to treat patients with atopic dermatitis.

83
Seeking AlphaMay 21

Pfizer: Added Value For A Defensive Pharma Portfolio

The terrain in biotech and pharma is getting treacherous, and it may be Big Pharma’s time to shine after, in some cases, decades of consolidation.

514

Earnings

$0.56
$0.66
$0.75
$0.85
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Jul 30, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.